Instructions to Authors 2014

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):
1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
   John G. Delinasios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2014 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Effect of Co-administration of Ketoconazole, a Strong CYP3A Inhibitor, on the Pharmacokinetics, Safety and Tolerability of Navitoclax, a First-in-class Oral Bel-2 Family Inhibitor, in Cancer Patients. A.H. SALEM, J. YANG, A. GRAHAM, A. PATNAIK, K. HOLEN, R. PRADHAN, H. XIONG (North Chicago, IL; San Antonio, TX; Cheshire, CT, USA; Cairo, Egypt) ................................................................. 2001

Impact of Combination Chemotherapy with Itraconazole on Survival for Patients with Recurrent or Persistent Ovarian Clear Cell Carcinoma. H. TSUBAMOTO, T. SONODA, M. YAMASAKI, K. INOUE (Nishinomiya; Kobe, Hyogo, Japan) ................................................................. 2007

Comparison of Common Terminology Criteria for Adverse Events v3.0 and Radiation Therapy Oncology Group Toxicity Score System After High-dose-rate Interstitial Brachytherapy as Monotherapy for Prostate Cancer. K. YOSHIDA, H. YAMAZAKI, S. NAKAMARA, K. MASUI, T. KOTSUMA, H. AKIYAMA, E. TANAKA, Y. YOSHIOKA (Takatsuki; Osaka; Suita, Osaka; Kyoto, Japan) ........................................................................................................................................................................................................ 2015

The Role of Prophylactic Hyperthermic Intraperitoneal Chemotherapy in the Management of Serosal Involved Gastric Cancer. E. SALADINO, F. FLERES, C. MAZZEO, V. PRUITI, M. SCOLLICA, M. ROSSITTO, E. CUCINOTTA, A. MACRÌ (Messina, Italy) ........................................................................................................................................................................................................ 2019


Phase I Study of Combination Therapy with Irinotecan, Leucovorin, and Bolus and Continuous-infusion 5-Fluorouracil (FOLFIRI) for Advanced Colorectal Cancer in Japanese Patients. Y. SASAKI, T. HAMAGUCHI, T. ARAI, A. GOTO, T. URA, K. MURO, Y. YAMADA, K. SHIRAO, Y. SHIMADA (Tokyo, Japan) ........................................................................................................................................................................................................ 2029


ABSTRACTS OF THE FIFTH INTERNATIONAL SYMPOSIUM ON VITAMIN D ANALOGS IN CANCER PREVENTION AND THERAPY. 2-3 May, 2014, Hotel Krefelder Hof, Krefeld, Germany ........... 2041
Novel Ruthenium – Gamma-linolenic Acid Complex Inhibits C6 Rat Glioma Cell Proliferation In Vitro and in the Orthotopic C6 Model In Vivo After Osmotic Pump Infusion. J.A. MIYAKE, M. BENADIBA, G. RIBEIRO, D. DE OLIVEIRA SILVA, A. COLOQUHOUN (São Paulo, SP, Brazil) ..............................

Radiosensitizing Effect of Rosmarinic Acid in Metastatic Melanoma B16F10 Cells. M. ALCARAZ, M. ALCARAZ-SAURA, D.G. ACHEL, A. OLIVARES, J.A. LÓPEZ-MORATA, J. CASTILLO (Murcia, Spain; Legon-Accra, Ghana) ..............................................

Synthesis and Antitumour Activity of a New Trinuclear Platinum Compound [{\textit{cis}}-PtCl(NH}_3\textit{)\textit{)}_2\textit{μ}{\textit{trans}}-Pt(3-hydroxypyridine)\_2\textit{H}_2\textit{N(CH}_2\textit{)\textit{)}_5\textit{NH}_2\textit{)}_2\textit{]}\_4\textit{Cl}_4 in Human Ovarian Cancer Cells. S.A. HAMAD, P. BEALE, J.Q. YU, F. HUQ (Lidcombe; Sydney, NSW, Australia) .......................................

A Bibenzyl from Dendrobium ellipsophyllum Inhibits Epithelial-to-Mesenchymal Transition and Sensitizes Lung Cancer Cells to Anoikis. C. CHAOTHAM, V. PONGRAKHANANON, B. SRITULARAK, P. CHANVORACHOTE (Bangkok, Thailand) ...........................................................

Clinical Studies

Pediatric Patients with Refractory Central Nervous System Tumors: Experiences of a Clinical Trial Combining Bevacizumab and Tensirolimus. S.A. PIHA-PAUL, S.J. SHIN, T. VATS, N. GUHATHAKURTA, J. AARON, M. RYT廷, E. KLEINERMAN, R. KURZROCK (Houston, TX; La Jolla, CA, USA) ..........................................................

An Early-stage, Non-hypervascular HCC Successfully Treated by Superselective, Bland Transarterial Embolization Using 40-μm Microspheres. T. TANAKA, S. MAEDA, H. NISHIOFUKU, T. MASADA, T. SATO, H. ANAI, H. SAKAGUCHI, K. KICHIKA (Kashiwara; Sango, Nara, Japan) ........................................

Bevacizumab Improves Splenomegaly and Decreases Production of Hyaluronic Acid After L-OHP Based Chemotherapy. Y. ARAKAWA, M. SHIMADA, T. UTSUNOMIYA, S. IMURA, Y. MORINE, T. IKEMOTO, J. HANAOKA, M. KANAMOTO, S. IWAHASHI, Y. SAITO, S. YAMADA, M. ASANOMA, C. TAKASU, Y. BANDO (Tokushima, Japan) ..........................................................

Full-dose Cisplatin and Oral Vinorelbine Concomitant with Radiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: A Multi-center Phase II Study. Ö. JUAN, A. SÁNCHEZ-HERNÁNDEZ, S. VÁZQUEZ, J. CASAL, J.L. FIRVIDA, F. APARISI, J. MUÑOZ, J. GARCÍA-SÁNCHEZ, R. GIRONÉS, M. LÁZARO, V. GINER (Valencia; Castellón; Lugo; Vigo; Ourense; Alco; Sagunto, Spain) .......

Multicenter Phase II Study of Second-line Cetuximab plus Folinic Acid/5-Fluorouracil/Irinotecan (FOLFIRI) in KRAS Wild-type Metastatic Colorectal Cancer: The FLIER Study. S. IWAMOTO, S. HAZAMA, T. KATO, Y. MIYAKE, M. FUKUNAGA, C. MATSUEDA, H. BANDO, J. SAKAMOTO, K. OBA, H. MISHIMA (Moriguchi; Sakai, Osaka; Ube, Yamaguchi; Nishinomiya; Amagasaki, Hyogo; Kanazawa, Ishikawa; Sapporo, Hokkaido; Kakamigahara, Gifu; Nagakute, Aichi, Japan) ..................................................


Oncological Outcomes of Hormonal Therapy with a Gonadotropin-releasing Hormone Agonist Combined with a Steroidal or Non-steroidal Antiandrogen in Patients with Prostate Cancer. T. IGAWA, T. TSURUSAKI, K. NOMATA, M. HAYASHI, M. FURUKAWA, H. SAKAI (Nagasaki; Omura; Sasebo, Japan) ..................................................

Multimodal Approach for Cervical Esophageal Carcinoma: Role of Neoadjuvant Chemotherapy. G. SUZUKI, H. YAMAZAKI, E. OGO, T. ABE, H. ETO, K. MURAKI, C. HATTORI, H. UMENO, T. NAKASHIMA, T. TANAKA, S. NAKAMURA, K. YOSHIDA (Kurume, Fukuoka; Kyoto, Tokyo; Takatsuki, Osaka, Japan) ..................................................

Contents continued on the preceding page
<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Synergistic Cytotoxic Activity of Treosulfan and Gemcitabine in Pancreatic Cancer Cell Lines</td>
<td>E. NITSCH, S. MINA, I. BRAMMER, A. PACE, G. SCHUCH, C. BOKEMEYER, A. ZANDER, N. KRÖGER, F. AYUK</td>
<td>Hamburg, Germany</td>
<td>1779</td>
</tr>
<tr>
<td>Antiproliferative and Apoptosis-inducing Activity of Nobiletin Against Three Subtypes of Human Breast Cancer Cell Lines</td>
<td>C. CHEN, M. ONO, M. TAKESHIMA, S. NAKANO</td>
<td>Fukuoka, Japan</td>
<td>1785</td>
</tr>
<tr>
<td>COX2 Inhibitor NS398 Reduces HT-29 Cell Invasiveness by Modulating Signaling Pathways Mediated by EGFR and HIF1-α</td>
<td>C. BOCCA, F. BOZZO, A. MIGLIETTA</td>
<td>Turin, Italy</td>
<td>1793</td>
</tr>
<tr>
<td>Activation of AXL and Antitumor Effects of a Monoclonal Antibody to AXL in Lung Adenocarcinoma</td>
<td>S. IIDA, Y. MIKI, T. SUZUKI, K. MORI, M. SAITO, H. NIKAWA, T. KONDO, H. YAMADA-OKABE, H. SASANO</td>
<td>Sendai, Miyagi; Shizuoka, Japan</td>
<td>1821</td>
</tr>
<tr>
<td>Effects of Angiotensin, Vasopressin and Aldosterone on Proliferation of MCF-7 Cells and Their Sensitivity to Doxorubicin</td>
<td>J.M. DELOU, A.G. LOPES, M.A. CAPELLA</td>
<td>Rio de Janeiro, RJ, Brazil</td>
<td>1843</td>
</tr>
<tr>
<td>Combinatorial Effects of PARP Inhibitor PJ34 and Histone Deacetylase Inhibitor Vorinostat on Leukemia Cell Lines</td>
<td>E. JASEK, M. GAJDA, G.J. LIS, M. JASINSKA, J.A. LITWIN</td>
<td>Krakow, Poland</td>
<td>1849</td>
</tr>
<tr>
<td>Curcumin Suppresses Vasculogenic Mimicry Capacity of Hepatocellular Carcinoma Cells through STAT3 and PI3K/akt Inhibition</td>
<td>K. CHIABLAEM, K. LIRDPRAPAMONGKOL, S. KEERATICHAMROEN, R. SURARIT, J. SVASTI</td>
<td>Bangkok, Thailand</td>
<td>1857</td>
</tr>
<tr>
<td>Potent Reactive Oxygen Species-Jnk-p38 Activation by Sodium Salicylate Potentiates Death of Primary Effusion Lymphoma Cells</td>
<td>K. VAETEEWOOTTACHARN, M. MITCHAI, P. SRIKOON, S. HATTORI, R. KARIYA, K. MATSUDA, S. WONGKHAM, S. OKADA</td>
<td>Kumamoto, Japan; Khon Kaen, Thailand</td>
<td>1865</td>
</tr>
<tr>
<td>The Influence of Retinoic Acid and Thalidomide on the Radiosensitivity of U343 Glioblastoma Cells</td>
<td>D. MILANOVIĆ, P. MAIER, D.H. SCHANNE, F. WENZ, C. HERSKIND</td>
<td>Mannheim; Freiburg, Germany</td>
<td>1885</td>
</tr>
<tr>
<td>Piperine Enhances the Efficacy of TRAIL-based Therapy for Triple-negative Breast Cancer Cells</td>
<td>S. ABDELHAMED, S. YOKOYAMA, A. REFAAT, K. OGURA, H. YAGITA, S. AWALE, I. SAIKI</td>
<td>Sugitani, Toyama; Tokyo, Japan</td>
<td>1893</td>
</tr>
</tbody>
</table>
Anticancer Activity of Novel Pyrido[2,3-b]indolizine Derivatives: The Relevance of Phenolic Substituents. A. BOOT, AL. BRITO, T. VAN WEZEL, H. MORREAU, M. COSTA, F. PROENÇA (Leiden, Netherlands; Braga, Portugal) ................................................................. 1673


Quercetin-3-O-glucoside Induces Human DNA Topoisomerase II Inhibition, Cell Cycle Arrest and Apoptosis in Hepatocellular Carcinoma Cells. S. SUDAN, H.P. VASANTHA RUPASINGHE (Truro, NS, Canada) ................................................................. 1691

Sodium Butyrate, a Histone Deacetylase Inhibitor, Regulates Lymphangiogenic Factors in Oral Cancer Cell Line HSC-3. T. YAMAMURA, N. MATSUMOTO, Y. MATSUE, M. OKUDERA, Y. NISHIKAWA, Y. ABIKO, K. KOMIYAMA (Tokyo; Matsudo, Chiba, Japan) ................................................................. 1701

Synergistic Inhibition of HCC and Liver Cancer Stem Cell Proliferation by Targeting RAS/RAF/MAPK and WNT/β-Catenin Pathways. R. GALUPPO, E. MAYNARD, M. SHAH, M.F. DAILY, C. CHEN, B.T. SPEAR, R. GEDALY (Lexington, KY, USA) ................................................................. 1709


Silibinin Down-regulates Expression of Secreted Phospholipase A2 Enzymes in Cancer Cells. A. HAGELGANS, B. NACKE, M. ZAMARAEVA, G. SIEGERT, M. MENSCHIKOWSKI (Dresden, Germany; Bialystok, Poland) ................................................................. 1723


Multidrug Resistance Reversing Activity of Newly Developed Phenothiazines on P-glycoprotein (ABCB1)-related Resistance of Mouse T-Lymphoma Cells. G. SPENGLER, D. TAKÁCS, Á. HORBÁTH, Z. RIEDL, G. HAJÓS, L. AMARAL, J. MOLNÁR (Szeged; Budapest, Hungary; Lisbon, Portugal) ................................................................. 1737

Quantitative Structure–Activity Relationship Analysis of Cytotoxicity and Anti-UV Activity of 2-Aminotropones. S. SEKINE, C. SHIMODAIRA, Y. UESAWA, H. KAGAYA, Y. KANDA, M. ISHIHARA, O. AMANO, H. SAKAGAMI, H. WAKABAYASHI (Sakado, Saítama; Kiyose, Tokyo, Japan) ................................................................. 1743

Translymphatic Chemotherapy Targeting Sentinel Lymph Nodes Using a Novel Phospholipid Polymer–Paclitaxel Conjugate. T. OYAMA, H. TAKEUCHI, S. MATSUDA, S. OZAWA, M. KITAJIMA, Y. KITAGAWA (Tokyo; Ishihara; Otawara, Tochigi, Japan) ................................................................. 1751

Dipalmitoleoyl-phosphatidylethanolamine Induces Apoptosis of NCI-H28 Malignant Mesothelioma Cells. Y. KAKU, A. TSUCHIYA, T. KANNO, T. NAKANO, T. NISHIZAKI (Nishinomiya, Hyogo, Japan) ................................................................. 1759

Metformin Suppresses Sonic Hedgehog Expression in Pancreatic Cancer Cells. M. NAKAMURA, A. OGO, M. YAMURA, Y. YAMAGUCHI, H. NAKASHIMA (Kurashiki; Okayama, Japan) ................................................................. 1765

A Novel Tetramethylnaphthalene Derivative Selectively Inhibits Adult T-Cell Leukemia (ATL) Cells In Vitro. M. TOYAMA, H. AÔYAMA, R. MUKAI, M. NAKamura, K. YOSHIMURA, M. OKAMOTO, T. OHISHIMA, Y. HASHIMOTO, M. BABa (Kagoshima; Tokyo; Sanuki, Kagawa, Japan) ................................................................. 1771

Contents continued on the preceding page
Effective Targeting of the Epidermal Growth Factor Receptor (EGFR) for Treating Oral Cancer: A Promising Approach. F.A. RIBEIRO, J. NOGUTI, C.T. OSHIMA, D.A. RIBEIRO (Santos, SP, Brazil) ........................................... 1547

Malignant Ascites in Ovarian Cancer and the Role of Targeted Therapeutics. E. SMOLLE, V. TAUCHER, J. HAYBAECK (Graz, Austria) ................................................................. 1553


New Anticancer Agents: Role of Clinical Pharmacy Services. D. LEVEQUE, A. DELPEUCH, B. GOURIEUX (Strasbourg, France) ................................................................. 1573

Subcutaneous Administration of Anticancer Agents. D. LEVEQUE (Strasbourg, France) ........................................... 1579

New Treatment Paradigm for Patients with Anaplastic Oligodendroglial Tumors. J. POLIVKA JR., J. POLIVKA, V. ROHAN, O. TOPOLCAN (Plzen, Czech Republic) ............................................................................................................................. 1587

Targeting Tropomyosin-receptor Kinase Fused Gene in Cancer. Y. CHEN, S.-H. TSENG (New Taipei; Taoyuan; Taipei, Taiwan, ROC) .......................................................... 1595

Experimental Studies

Cytotoxic Activity of N, N’-Bis (2-hydroxybenzyl) ethylenediamine Derivatives in Human Cancer Cell Lines. M.A. MUSA, V.L.D. BADISA, L.M. LATINWO (Tallahassee, FL, USA) ................................................................. 1601

The Addition of a Pregnenolone Pendant Group Enhances the Anticancer Properties of Titanocene Dichloride in a MCF-7 Xenograft Model. G. RAMOS, Y. LOPERENA, G. ORTIZ, F. REYES, A. SZETO, J. VERA, J. VELEZ, J. MORALES, D. MORRERO, L. CASTILLO, S. DHARMAWARDHANE, E. MELENDEZ, A.V. WASHINGTON (Bayamón; Mayagüez; San Juan, PR, USA) ................................................................. 1609

Ascorbic Acid Induces either Differentiation or Apoptosis in MG-63 Osteosarcoma Lineage. M.T. VALENTI, M. ZANATTA, L. DONATELLI, G. VIVIANO, C. CAVALLINI, M.T. SCUPOLI, L.D. CARBONARE (Verona, Italy) ................................................................. 1617

Bosutinib Reduces the Efficacy of Dasatinib in Triple-negative Breast Cancer Cell Lines. M. TARPLEY, T.T. ABDISSA, G.L. JOHNSON, J.E. SCOTT (Durham; Chapel Hill, NC, USA) ................................................................. 1629

Specific RSK Kinase Inhibition by Dibenzyl Trisulfide and Implication for Therapeutic Treatment of Cancer. H.I.C. LOWE, C.O.B. FACEY, N.J. TOYANG, J.L. BRYANT (Kingston, Jamaica, West Indies; Wellington, FL; Baltimore, MD, USA) ................................................................. 1637

Mechanisms by which Synthetic 6,7-Annulated-4-substituted Indole Compounds with Anti-proliferative Activity Disrupt Mitosis and Block Cytokinesis in Human HL-60 Tumor Cells In Vitro. J.-P.H. PERCHELLET, E.M. PERCHELLET, C.R. SINGH, M.T. MONNETT, E.R. STUDER, P.D. THORNTON, N. BROWN, D. HILL, B. NEUENSWANDER, G.H. LUSHINGTON, C. SANTINI, K.R. BUSZEK (Manhattan; Lawrence, KS; Kansas City, MO, USA) ................................................................. 1643

Cytarabine-resistant Leukemia Cells Are Moderately Sensitive to Clofarabine In Vitro. T. YAMAUCHI, K. UZUI, R. NISHI, H. SHIGEMI, T. UEDA (Hiieiji, Fukui, Japan) ................................................................. 1657

Inhibitory Effect of Orally-administered Sulfated Polysaccharide Ascophyllan Isolated from Ascophyllum nodosum on the Growth of Sarcoma-180 Solid Tumor in Mice. Z. JIANG, R. ABU, S. ISAKA, S. NAKAZONO, M. UENO, T. OKIMURA, K. YAMAGUCHI, T. ODA (Nagasaki, Japan; Shimonoseki, Yamaguchi, Japan) ................................................................. 1663